Xenetic Biosciences, Inc. (XBIO) intrinsic value & 10-year financials
Xenetic Biosciences, Inc. (XBIO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 0.1% a year to $3.0M, with an average return on invested capital of -239.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.99
- Market cap
- $3.4M
- Revenue (FY2025)
- $3.0M
- Revenue growth (10-yr CAGR)
- -0.1%
- ROIC (10-yr avg)
- -239.5%
- Free cash flow (FY2025)
- —
XBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.0M | -$2.7M | -$1.58 | — | -95.2% | — |
| FY2024 | $2.5M | -$4.0M | -$2.57 | — | -168.2% | — |
| FY2023 | $2.5M | -$4.1M | -$2.71 | — | -177.8% | — |
| FY2022 | $1.7M | -$6.6M | -$0.46 | — | -393.6% | — |
| FY2021 | $1.2M | -$5.6M | -$0.55 | — | -495.1% | — |
| FY2020 | $436.9K | -$10.9M | — | — | -3189.8% | -290.8% |
| FY2019 | $17.1K | -$12.8M | — | — | -75511.7% | -188.3% |
| FY2018 | $0 | -$7.3M | — | — | — | — |
| FY2017 | $7.6M | -$3.6M | — | $1.5M | -47.1% | — |
| FY2016 | $3.0M | -$54.2M | — | -$8.8M | -1581.0% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Xenetic Biosciences, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Xenetic Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -2.4% ROIC.
Xenetic Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Xenetic Biosciences, Inc. is modeled at -0.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-11.34 per share.